Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arcturus Therapeutics Holdings Inc ARCT

Healthcare Biotechnology
Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid... see more

Recent & Breaking News (NDAQ:ARCT)

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

Business Wire November 4, 2020

Arcturus Therapeutics to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Nov 9, 2020

Business Wire October 30, 2020

Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency

Business Wire October 5, 2020

Arcturus Therapeutics to Present at Guggenheim's Vaccines and Infectious Diseases Conference

Business Wire October 1, 2020

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

GlobeNewswire September 8, 2020

Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate

GlobeNewswire September 4, 2020

LD Micro - 360 Companies Set to Present this Week

Accesswire August 31, 2020

Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health

GlobeNewswire August 18, 2020

Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR(TM) mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study

GlobeNewswire August 11, 2020

Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update

GlobeNewswire August 10, 2020

Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer

GlobeNewswire August 6, 2020

Arcturus Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020

GlobeNewswire August 4, 2020

Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire July 31, 2020

Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock

GlobeNewswire July 29, 2020

Arcturus Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire July 28, 2020

Arcturus Therapeutics Announces Agreement with Israeli Ministry of Health to Supply COVID-19 Vaccine Candidate, LUNAR-COV19

GlobeNewswire July 23, 2020

Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Phase 1/2 Clinical Trial for COVID-19 Vaccine Candidate, LUNAR-COV19

GlobeNewswire July 21, 2020

Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board

GlobeNewswire July 1, 2020

Arcturus Therapeutics to be Added to Russell 2000® Index

GlobeNewswire June 29, 2020

Arcturus Therapeutics to Present at the Raymond James Human Health Innovation Virtual Conference

GlobeNewswire June 11, 2020